Completed Studies | Type 1 Diabetes TrialNet

Information

for you...

Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.

T1D
Families

We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.

Study
Participants

While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.

Healthcare Professionals

Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.

Researchers

Research is at the heart of our T1D family. Learn about TrialNet samples and data here.

Each study gives us important information.

Once a study ends and findings are analyzed, we share the results with the participants, scientific community, and public.

No matter what the results, every study gives us important information to carefully evaluate current thinking and moves us one step closer to a future without T1D.

Completed TrialNet Studies

ATG/GCSF

ATG/GCSF was designed to build on prior findings of a pilot study suggesting thymoglobulin (ATG) combined with pegylated granulocyte colony stimulating factor (GCSF) preserved insulin production for more than 1 year after treatment in people who had type 1 diabetes for 4 months to 2 years. Learn more

Oral Insulin

TrialNet tested the drug Oral Insulin to see if it can delay or prevent T1D (stage 1) from progressing to stage 2 and ultimately prevent clinical diagnosis (stage 3). Learn more

Teplizumab (Anti-CD3)

We tested the drug teplizumab to see if it could delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production. Learn more